Study on prevalence and correlation of liver function abnormalities in heart failure patients in Tirunelveli Medical College Hospital by Karthika, M
1 
 
STUDY ON PREVALENCE AND 
CORRELATION OF LIVER FUNCTION 
ABNORMALITIES IN HEART FAILURE 
PATIENTS IN TIRUNELVELI MEDICAL 
COLLEGE HOSPITAL 
Dissertation submitted to 
THE TAMIL NADU DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI, TAMILNADU 
  in partial fulfillment for the Degree of 
DOCTOR OF MEDICINE - BRANCH I GENERAL MEDICINE 
MAY 2018 
TIRUNELVELI MEDICAL COLLEGE HOSPITAL 
TIRUNELVELI - 11, TAMIL NADU
 
2 
 
CERTIFICATE 
This is to certify that the dissertation entitled “ STUDY ON PREVALENCE 
AND CORRELATION  OF LIVER FUNCTION ABNORMALITIES  IN 
HEART FAILURE PATIENTS”  submitted  by  Dr.M.KARTHIKA  to The 
Tamil Nadu Dr. M.G.R. Medical University, Chennai, in partial fulfillment for 
the award of  M.D. Degree (GENERAL MEDICINE) is a bonafide work carried 
out by her under my guidance and supervision during the course of study 2015-
2018. This dissertation partially or fully has not been submitted for any other 
degree or diploma of this university or other. 
 
 
PROF.DR.M.RAVICHANDRAN., M.D., 
CHIEF-II ND MEDICAL UNIT, 
DEPARTMENT OF MEDICINE, 
TIRUNELVELI MEDICAL COLLEGE, 
TIRUNELVELI - 627011 
PROF.DR.A.S.MOHAN, M.D., 
PROFESSOR AND HEAD OF DEPARTMENT, 
DEPARTMENT OF MEDICINE, 
TIRUNELVELI MEDICAL COLLEGE, 
TIRUNELVELI - 627011 
 
 
                              PROF. DR. K. SITHY ATHIYA MUNAVARAH. M.D 
                                                                           THE DEAN, 
                               TIRUNELVELI MEDICAL COLLEGE, TIRUNELVELI - 627011 
3 
 
DECLARATION 
I solemnly declare that the dissertation titled “STUDY ON PREVALENCE 
AND CORRELATION  OF LIVER FUNCTION ABNORMALITIES IN 
HEART FAILURE PATIENTS" is prepared by me. 
The dissertation is submitted to THE TAMILNADU Dr. M.G.R. MEDICAL 
UNIVERSITY towards the partial fulfillment of requirements for the award of 
M.D. Degree (Branch I) in General Medicine. I also solemnly declare that this 
bonafide work or a part of this work was not submitted by me or any others for 
any award, degree, diploma to any university, found either in India or abroad. 
 
 
 
Place: Tirunelveli. 
Date: 
Dr.M.KARTHIKA , 
Post graduate student, 
M.D. General Medicine, 
Department of General Medicine, 
Tirunelveli Medical College, 
Tirunelveli - 627011. 
 
                               
  
4 
 
ACKNOWLEDGEMENT 
                                   First of all I like to express my sincere gratitude and 
indebtedness for our beloved Prof. Dr. M.RAVICHANDRAN, M.D., Chief, 
 IInd  Medical Unit, Tirunelveli Medical College, who stayed as a constant 
inspiration for my study and for his expert guidance and support throughout my 
course. 
                           It is of immense gratitude that I like to thank our beloved, 
caring Prof. DR. A.S. MOHAN, M.D., Professor and Head, Department of 
General Medicine, Tirunelveli Medical College for his kind advice, 
encouragement and support. 
                            I sincerely thank our Dean Prof. Dr. K. SITHY 
ATHIYA MUNAVARAH. M.D.,for permitting me to carry out this study in 
Tirunelveli Medical College Hospital. 
                        I am thankful to my Assistant Professors, DR.C.THOMAS 
KINSLEY,M.D.,DR.P.SANKARANARAYANAN,M.D.,D.M,DR.V.RAJESH 
BABU,M.D. for their help and valuable suggestions. 
                         I thank my co-postgraduates and C.R.R.Is for their 
valuable help and support. 
                       I sincerely thank all the PATIENTS who cooperated with 
me for participating in the study. 
5 
 
                       Last but not the least, I thank almighty god, for giving me 
wisdom, favours and blessing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
 
 
7 
 
CERTIFICATE - II 
 This is certify that this dissertation work title “STUDY ON 
PREVALENCE AND CORRELATION  OF LIVER FUNCTION 
ABNORMALITIES  IN HEART FAILURE PATIENTS” of the candidate 
Dr.M.KARTHIKA  with registration Number 201511355 for the award of 
M.D. in the branch of GENERAL MEDICINE. I personally verified the 
urkund.com website for the purpose of plagiarism check. I found that the 
uploaded thesis file contains from introduction to conclusion page and result 
shows 1 percentage of plagiarism in the dissertation. 
 
Guide & Supervisor sign with Seal. 
  
8 
 
 
  
9 
 
 
 
 
 
 
 
 
 
 
                               
  
10 
 
CONTENTS 
 
  
ANNEXURES: 
 PROFORMA 
 MASTER CHART 
 KEY TO MASTER CHART 
 ABBREVIATIONS 
 CONSENT FORM 
 
 
 
 
S.NO 
 
CONTENTS 
 
PAGE NO 
1. INTRODUCTION 9 
2. AIMS OF STUDY 12 
3 REVIEW OF LITERATURE 14 
4. METHODS AND MATERIALS 57 
5 OBSERVATIONS AND RESULTS 61 
6. DISCUSSION 87 
7. SUMMARY 94 
8. CONCLUSION 95 
9. LIMITATIONS OF THE STUDY 96 
10. BIBLIOGRAPHY  
11 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              
  
12 
 
                                             The clinical syndrome of heart failure encompasses 
many clinical features that negatively affects almost all the vital organs in the 
body. These features can be due to both systolic failure as well as the diastolic 
feature whose nomenclature has undergone recent modifications as that heart 
failure with reduced ejection fraction and heart failure with preserved ejection 
fraction respectively. Even though there many studies regarding the affection of 
renal system in cases of heart failure ,the liver with its dual supply bears the 
brunt of  both types of heart failure leading onto derangement of its functions. 
The liver is a multi faceted organ with high level of metabolic functions and 
hence is highly dependent on hepato-cardiac vascular connections, both arterial 
supply to provide high oxygen supply and venous drainage to remove the 
catabolic waste products. As a result of the hepatic dysfunction, there occurs 
many of biochemical alterations in the liver function tests that are usually 
measured in patients admitted for treatment. These abnormalities not only bare 
open the effects of heart failure over liver but may also help in the assessing the 
severity of the failure as well prognostication of the acute as well as the chronic 
heart failure patients. Hence the study on effects of both types of  heart failure 
on the liver  becomes more important in the evolving scenario of cardiac 
morbidity and mortality. 
                                             This study is based on the need for assessing 
prevalence of liver dysfunction and its implications correlating the biochemical 
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alterations of liver function with the severity of heart failure patients in the 
Tirunelveli Medical College. With a start up study of this kind, the emerging 
use of liver function test  for assessing and obtaining the  severity of heart 
failure patients without major invasive and expensive investigations  can be 
considered . It can also be extrapolated to use in primary care and secondary 
care settings in the state of Tamilnadu which is one of leading state in 
healthcare in India.   
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AIMS OF THE STUDY 
 
                                1.To study prevalence of liver function abnormalities in 
heart failure patients using liver function tests.  
                               2. To correlate the  liver function tests abnormalities with 
Clinical,Biochemical and Radiological severity of heart failure patients. 
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HEART FAILURE 
                                  Heart failure syndrome produces great deal of great 
morbidity and mortality overload on the health systems of developed and 
developing countries in terms of health, economic and social aspects. The 
population that is affected by heart failure is growing exponentially with that of 
aging of social demography, improved treatment and survival after myocardial 
infarction and also prevention of sudden cardiac death to an extent (2). Heart 
failure syndromes can be classified as : 
1)   Acute heart failure 
2) Chronic heart failure 
                                    The recent classification of heart failure focuses upon the 
function of the left ventricular system and hence they are now classified as : 
                    1) Heart failure with reduced ejection fraction (EF <40%) 
                    2) Heart failure with preserved ejection fraction(EF >40%) 
ETIOLOGY: 
Heart failure with reduced ejection fraction (1) : 
 1) coronary artery disease 
 2) chronic volume overload-  regurgitant lesions, intra and extra cardiac 
shunting 
 3) chronic pressure overload-  hypertension , obstructive lesions 
 4) chronic lung disease- cor pulmonale , pulmonary vascular disorders 
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 5) non ischemic dilated cardiomyopathy- infiltrative, familial 
 6) toxic / drug induced  
 7) infections –viral, Chagas disease 
 8) rate and rhythm disorders- chronic bradyarrythmias and chronic 
tachyarrythmias 
Heart failure with preserved ejection fraction (1) : 
1) hypertrophy –hypertrophic cardiomyopathy, hypertension 
2) age 
3) restrictive cardiomyopathy- amyloidosis, sarcoidosis, 
hemochromatosis 
4) fibrosis 
5) obesity 
6) endomyocardial disorders 
High output states (1) : 
1) thyrotoxicosis 
2) nutritional disorders- beriberi 
3) chronic anemia 
4) systemic arterio-venous shunting   
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PATHOPHYSIOLOGY OF HEART FAILURE (3): 
                                            Heart failure is a complex clinical syndrome that can 
defined in terms of dysfunction that is associated with structural as well as 
functional compromise of myocardium resulting in typical symptoms of 
breathlessness and easy fatiguability. The models that described heart failure 
such as ‘cardiorenal model’ endorsing the effects of excessive salt and water 
retention or the ‘cardiocirculatory’ model emphasizing the abnormality in the 
pumping mechanism of heart with its output capacity are not well accepted. The 
main baseline of heart failure is the impaired ability of myocardial pump to act 
as an effective pump maintaining the circulation and perfusion of the bodily 
systems. The different set of adjustments and acclimatizations that occur in the 
setting of the heart failure decide and contribute to the progressive long term 
morbidity and mortality of heart failure patients. 
                                          Acute events like myocardial infarctions, myocarditis 
or events with slow onset such as acquired cardiomyopathies, hypertensive 
heart disease, valvular heart disease and genetic cardiomyopathies will all lead 
to the decline in the pumping capacity or filling capacity affecting the systolic 
and diastolic functions respectively. This signifies the variable nature of the 
symptoms that would be associated with heart failure varying from being 
asymptomatic to severe dyspnoea, fatigue and mortality. These symptoms 
associated not only are dependent on the onset but also the effects of the 
compensatory mechanisms that get activated once heart failure propagates and 
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sustains itself in long term. The specific pathology that lies central any heart 
failure which is the ‘Left Ventricular remodeling’ occurs with the sustained 
activation of the neurohormonal system . This type of remodeling could 
possibly by itself lead onto the progression of heart failure and can affect the 
ejection fraction of left ventricle . 
 The mechanism behind the model heart failure are (3) : 
1) Neurohormonal mechanisms- 
2) Left ventricular remodeling 
Neurohormonal mechanisms: 
                                         Eventhough the term ‘neurohormonal’ signifies the 
original thought of molecules that were produced in the neuroendocrine system , 
recent concepts suggest that all those molecules like nor epinephrine (NE) and 
angiotensin 2(AG2) are produced in the myocardial fibres itself and act as 
paracrine or autocrine manner creating a unitary concept of ‘ neurohormonal 
theory’. 
Symphathetic system activation :- During the early course of heart failure , the 
symphathetic system starts to get stimulated with the concominant suppression 
of the parasymphathetic system in the body due to the inhibitory inputs received 
from the baroreceptors such as carotid and aortic barreceptors but also due to 
the increase in the excitatory inputs from the metaboreceptors and peripheral 
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chemoreceptors (6). The net result due to this activation is the loss of normally 
occurring heart beat variability as well as increased peripheral resistance with 
the increase in the symphathetic stimulation. There is also increase in the nor-
epinephrine discharge and concentration in the circulating blood. This increase 
in norepinephrine levels are not sustained in the long term due the exhaustion of 
the cardiac reserves in the myocardial interstium  and also the down regulation 
of enzyme complex of tyrosine hydroxylase which is needed for norepinephrine 
production. 
                                               Due to the elevated levels of symphathetic 
activation molecules in the body , the beta adrenergic receptor activation leads 
to increase in heart rate and also the force of contraction while the alpha 
adrenergic activity increase to produce the dominant effect of peripheral 
vasoconstriction. It is clear from this points that the symphathetic system 
overdrive helps in the short trem compensation of effects of the pump failure in 
heart failure patients while in long term these effects can lead onto the 
maladaptive processes taking over to produce left ventricular dysfunction either 
in terms of systolic or diastolic dysfunction. Two large ongoing trials such as 
INNOVATE HF and NECTAR HF  are examining the effects of vagal nerve 
stimulation on the left ventricular structure  and the clinical outcomes in New 
York Heart Association (NYHA) class 3 failure patients. 
Renin Angiotensin aldosterone system: (RAAS) 
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                                                RAAS  is activated only in the later stage of heart 
failure unlike the symphathetic system (6) . This activation of  RAAS can be due 
to either the associated hypoperfusion of the renal vasculature or the decrease in 
the filtered load of sodium reaching the sensing organs of macula densa situated 
in the distal nephron along with concomitant increase in the activity of 
symphathetic system leading onto activation of RAAS  and secretion of the 
renin in the blood. The logical final step in RAAS activation is the production 
on Angiotensin 2 (AG2) which is by far the most potent major vasoconstrictor 
substance . The production of AG2 can occur through two pathways : 
1) Angiotensin converting enzyme (ACE)  dependent 
pathway 
2) Angiotensin converting enzyme (ACE)  independent 
pathway 
                                              ACE dependent pathway occurs 90% in the 
peripheral tissues while the remaining 10% occurs in the heart and its blood 
vessels, while the ACE independent pathways are through the activation of 
chymase, kallikrein and cathepsin G pathways leading onto to the fact that ACE 
inhibitors alone cannot lead onto complete suppression of the Angiotensin 
production having major implications in the treatment of heart failure. 
Angiotensin (AG2) exerts its effect mainly through two receptors ,namely, 
angiotensin receptor 1(AT1) and receptor 2(AT2). The first receptor is 
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predominantly seen with the  vascular  channels of our body while that the AT 2 
receptor are mainly seen the heart muscles and the fibroblasts within it. In the 
later stages of the heart failure , the AT1/AT2 receptor ratio is decreased leading 
onto the vasodilatation, natriuresis and the increased secretion vasodilators such 
as bradykinin .(6) 
                                           The sustained elevation of AT 2 receptors will lead 
onto maladaptive changes in the heart in the long term effect producing fibrosis 
and enhanced secretion of norepinephrine along with aldosterone secretion due 
to stimulation of zona glomerulosa (5) . This effect of increased aldosterone may 
aid in the excretion of potassium while that of fibrosis and decreased ventricular 
compliance and increased stiffness due to fibrosis. The importance of 
aldosterone lies in the fact that in addition to sodium retention , it can also 
provoke endothelial dysfunction, baroreceptor  dysfunction and inhibition of 
norepinephrine release along with increased oxidative stress. 
                                                  Oxidative free radicals are formed as result of 
metabolic activity exceeding the ability of the body systems to scavenge them 
properly . The increase in production of oxygen radicals that cause severe 
metabolic stress on the failing myocardium are due to mechanical strain 
imposed , neurohormonal stimulation and elaboration of the inflammatory 
cytokines. Aldosterone antagonists play an important role in prevention of 
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morbidity and decreased hospitalizations of heart failure patients which have 
been confirmed in many trials . 
Alterations in renal functions: 
                                                  These alterations that occur in renal system and 
its function are primarily due to the decrease in the effective intravascular 
volume leading onto to decreased filling of the ventricles inspite of the patient 
being in volume overload condition where the fluids accumulate in the 
interstitial space. This process of alterations occur mainly due to the decrease in 
effective cardiac output rather than “forward failure” model suggesting 
increased sodium reabsorption due to renal hypoperfusion or the “backward 
failure” model suggesting the increased transudation of salt and water from the 
intravascular space to the extravascular compartment (2). These impulses cause 
baroreceptor mechanisms to get activated thereby causing sustained 
symphathetic stimulation. The profound effects of volume overload occurring 
with renal dysfunction is coupled with the release of arginine vasopressin 
(AVP) which contributes to decreased water as well as solute excretion. 
Circulating AVP are seen in greater amounts in heart failure patients which may 
cause hyponatremia ( even after the blood osmolality is corrected) (7) .  
                                              The effects of symphathetic stimulation, RAAS 
activation and AVP over secretion  can be blunted by the counter regulatory 
vasopeptides comprising of prostaglandins, atrial natriuretic paptide (ANP), 
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brain natriuretic peptide(BNP) . Natriuretic peptides are released in response to 
the activation of the stretch receptors in the myocardium . These peptides offset 
the effects of the neurohormonal affects previously described causing 
progression in heart failure  Natriuretic peptides are of five types: ANP -Atrial 
natriuretic peptide, BNP- Brain natriuretic peptide, CNP, DNP, Urodilantin (6). 
                                             These natriuretic peptides act on different receptors, 
namely, A receptor( ANP & BNP), B receptor (only by CNP) which are 
coupled to the guanylcyclases resulting in natriuresis, inhibition of fibrogenic 
stimuli and vasorelaxation occurring due to decreased RAAS stimulation. The 
other receptor is of C type is for the degradation of the natriuretic peptides 
which are cleared by the neutral endopeptidases, otherwise called as 
nephrilysin. The use of aldosterone antagonists, nephrilysin inhibition had 
produced good results showing great impact on the left ventricular structure and 
function in patients with heart failure with preserved ejection fraction. (7) 
Alterations in peripheral vasculature:- In patients suffering from chronic heart 
failure , the interacting autonomic and local autoregulatory mechanisms 
preserve the circulation of essential organs like brain and heart while decreasing 
the blood supply to visceral organs and gut. During exercise, there is increase 
demand of blood from the skeletal muscles in already decompensated patients, 
there is potential stimulation of symphathetic system which leads onto 
peripheral vasoconstriction. There are many vasoconstrictors in play in this 
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process which includes norepinephrine, endothelin, urotensin, neuropeptide Y , 
thrombaxane A2 and AVP. 
Left Ventricular Remodelling: 
                                                       Even though the neurohormonal model of 
heart failure lays emphasis on the stabilization and certain reversibility in the 
process of heart failure , the truth is that this process once started will definitely 
progress at one rate or another . Many published review have shown that the 
process of Left ventricular remodeling has a direct bearing on the left 
ventricular performance and thereby the deterioration of left ventricle including 
the progression of heart failure. 
                                                       The left ventricular remodeling has been 
traditionally discussed in terms alteration in the cardiac myocyte, changes in the 
volume of myocyte and non myocyte cells, geometry and architecture of the 
LV. 
The pattern of cardiac hypertrophy occurs in two basic patterns. They are: 
Concentric hypertrophy (3):-  In case like aortic stenosis or hypertension ,the 
systolic wall stress increases result in addition of sarcomeres in parallel ,an 
increase in the cross sectional area and increased left ventricle thickening . This 
concentric hypertrophy has been linked with alteration in calcium/calmodulin 
dependent protein kinase 3 dependent pathway. 
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Eccentric hypertrophy  (3)  :-  In case of regurgitant lesions like mitral and aortic 
insufficiency , increase in the diastolic wall stress leads to increase in myocyte 
length as well as addition of myocyte in series producing left ventricular 
enlargement which has been linked to AKT pathway. The myocyte arrangement 
occurs in heart failure cases has elongated morphology with or without left 
ventricle wall thickening. 
                                               The normally elliptical chamber cross section of 
the left ventricle will turn into a spherical chamber after left ventricle 
remodeling producing additive meridional stress on the walls of myocardial 
pump. This load that is excessively produced is transferred onto the ventricles 
both during the systole as well as diastole thereby increasing the energy 
expenditure of the myocardium. The proportionate left ventricle wall thinning 
occurs with the increasing end diastolic pressure and volume. This leads onto 
the functional afterload mismatch on the the heart producing further decrease in 
the cardiac output. This stress will cause increase secretion of stretch receptor 
activated vasopeptides pathways  and hypertrophic pathways. These changes 
cause episodic hypoperfusion of the subendocardial myocytes, increased 
amount of oxidative stress and increased free radical injury. The most serious 
and important mechanical complication is the pulling apart of the papillary 
muscles leading onto “functional mitral insufficiency”. 
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                                                    Most the the medical and device assisted 
therapy lead onto decrease in left ventricular mass and volume restoring the 
ventricle to its original mass and size , a process known as ‘reverse ventricular 
remodeling’or  ‘myocardial recovery’ (3). Myocardial remission refers to 
normalization of morphologic changes even when there are factors provoking 
heart failure while myocardial recovery signifies normalization with freedom 
from subsequent heart failures. 
Clinical features : 
Symptoms: 
1) fatigue-  it is mainly related to low cardiac output, anemia and skeletal 
muscle abnormalities 
2) dyspnoea – it is multifactorial  in origin and occurs due to stimulation of 
sensors such as stretch receptors, metaboreceptors and juxta capillary J 
receptors which results in shallow breathing , typical of cardiac origin. 
3) orthopnoea - Dyspnoea that occurs in recumbent position due to fluid shift 
into the intravascular compartment from interstitial space which gets relieved 
with sitting upright. 
4)PND- Paroxysmal Nocturnal dyspnoea refers acute episode of dyspnoea and 
coughing usually 1-3 hrs awakening the patient from bed 
 5) Nocturnal cough, oliguria, nocturia, insomnia 
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6)Abdominal distension due to fluid collection, right upper quadrant pain due to 
stretching of liver capsule and dependent edema. 
Signs: 
1) reduction in blood pressure, tachycardia, narrowing of pulse pressure 
2) laboured breathing, cyanosis 
3) elevated jugular venous pressure, giant ‘v’ waves in tricuspid regurgitation 
4)pulmonary crackles, expiratory wheeze, pleural effusions 
5) Tender hepatomegaly,  jaundice, ascites and peripheral edema  
6) Displaced apical impulse, third heart sound, fourth heart sound (diastolic 
failure) 
Criteria used to diagnose heart failure – Framingham heart study, NHANES 
criteria 
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Criteria: 2 major criteria or 1 major criterion in conjunction with 2 minor 
criteria in Framingham study and 3 points in NHANES study 
 
LABORATORY TESTS : 
1) Routine blood tests such as complete hemogram , panel of  electrolytes , 
renal and liver function tests, serum uric acid, assessment for diabetes, 
dyslipidemia and thyroid functions are to be done. 
2) Electrocardiogram  reveals the  rate, rhythm , chamber enlargement, evidence 
of previous  ischemia and also to look for QRS length to decide the patient for 
cardiac resynchronization. 
3) Chest X-ray says about the cardiac size, shape and pulmonary edema if any. 
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4) Assessment of  LV function  is done through the non invasive means like 
echocardiography/Doppler as well as Magnetic resonance imaging  by which 
ejection fraction as a measure of contractility ac be assessed along with right 
ventricular and pulmonary vasculature changes , tissue & pulse wave Doppler to  
assess diastolic dysfunction . 
5) Bio markers such as B Type Natriuretic Peptide (BNP) , N-terminal Pro BNP 
, galectin and soluble ST-2 protein have been measured ,correlated well with the 
incidence as well as the severity of heart failure and are helpful with optimizing 
the dosage in relation to varying levels of the markers. 
6) Exercise testing is done rarely and useful to assess the need for cardiac 
transplantation if the peak oxygen uptake of  <14 ml/kg which is usually  
associated with poor prognosis. 
Management  of heart failure: 
1) Acute decompensated disease (3) : 
 General measures: 
*) Identifying the problem and evaluation regarding nonadherence of 
medications, cardiac stimulant usage, active infections, thrombo embolisms 
,arrhythmias which tend to precipitate heart failures should be done and 
assessment done accordingly. 
*) A parallel step is to stabilize the patient’s hemodynamic status. 
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Specific measures : 
              
*) Volume management : 
                              Diuretics remain the mainstay of volume balance in these 
patients with usage of thiazides like metazolone in combination with loop 
diuretics like frusemide having synergistic effect and they can be given either as 
high dosage regimen or continuous infusion when there is poor oral absorption 
and need for rapid relief . They are continued till the patient achieves 
euvolemia. In late stages of heart failure reduced use of diuretics and continued 
inotropic support have helped to maintain the renal perfusion , thereby 
preventing cardiorenal syndrome progression.the use of ultrafiltration in 
refractory cases have the potential advantages such as neutral effect on serum 
electrolytes , controlled fluid removal and decreased neurohormonal activity. 
Cardio Renal Rescue Study in Acute Decompensated  Heart Failure ( CARESS 
–HF) trial shows no mortality benefits from ultrafiltration when compared to 
conventional pharmacotherapy. 
*) Vascular Therapy: 
                     Use of intravenous nitrates, nitroprusside and nesiritide are 
considered with nesiritide showing increased incidence of renal dysfunction and 
hypotensive episodes. Serelaxin or human recombinant human relaxin -2 has 
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been used to improve dyspnoea, symptoms of congestion and less worsening of 
heart failure. 
*) Inotropic support : 
                    Milrinone and dobutamine are the commonly used inotropes in the 
setting of low output cardiac failure cases which relieve the congestion rapidly 
by virtue of their action on myocardial contractility . Milrinone score s over 
dobutamine since it acts downstream on beta receptors hence used in patients on 
beta blocker therapy. Novel inotropes such as levosimendan and Omecamtiv are 
being considered due to their action on myofilament sensitization rather then 
increasing calcium concentration in myofibrils (7). 
2)Heart failure with reduced ejection fraction :  
                           Renocentric ( diuretics ) and hemodynamic models ( digoxin 
and inotropes ) have been replaced with the neurohormonal models involving 
ACEI( Angiotensin Converting Enzyme Inhibitors) and beta blockers leading 
onto increased improvement in cardiac structure with relief of symptoms. 
Neurohormonal antagonism : 
                                         ACEI s, ARBs ( Angiotensin Receptor Blocker) and 
beta blocker therapy have decreased both morbidity and mortality of heart 
failure patients even in advanced states (7) . While these effects are seen as a 
class effect in ACEIs , beta blockers efficiency is limited to specific drugs like 
bucindolol and xamoterol which have intrinsic sympathomimetic activity. Both 
these drugs have dose dependent decrease in morbidity and hospitalizations 
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helping in easy titration every two weeks. ARBs have the potential to neutralize 
the “Aldosterone Escape “  that occurs with chronic ACEIs therapy (6). 
                                       Mineralocorticoid antagonists like spironolactone and 
selective drugs like eplerenone have again reduced hospitalizations in 
symptomatic  NYHA III & IV class patients . Hyperkalemia and worsening 
renal functions are main impediments to upward  titration of these drugs . 
Arteriovenous vasodilators : 
                   Drugs such as hydralazine and nitrates by producing systemic 
vasodilatation have helped in improving the failure symptoms to an extent in 
patients who are not tolerant to neurohormonal blockade due to worsening renal 
functions and hyperkalemia. 
Inotropes : 
                                         Digitalis glycoside exert mild inotropic and 
symphatho- inhibitory effects and attenuate the carotid  baroreceptor reflexes 
decreasing serum rennin and aldosterone levels. Low doses of digoxin are 
sufficient to produce beneficial effects while higher doses are associated with 
potential mortality risks. 
Others : 
                                         Ivabradine is a inhibitor of cardiac  If   current in the 
sinoatrial node leading onto slowing of heart rate with  no negative inotropic 
effect. Diuretics are needed at the outset to correct hypervolemia before the 
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neurohormonal therapy sets in . Newer calcium channel inhibitors like 
amlodipine and felodipine have morbidity benefits while statins and 
anticoagulants have not demonstrated potential benefits . Micronutrients like 
fish oil with long chain omega unsaturated fatty acids and thiamine in chronic 
heart failure patients have led to improved outcomes and reduced 
hospitalizations .   
                                       Enhanced External Counterpulsation ( EECP) using  
graded external pneumatic compression of peripheral lower extremities which is 
administered in 1 hour sessions for 35 treatment days  has been proposed to 
reduce symptoms as well as exercise induced ischemia .Cardiac 
Resynchronization Therapy helps in more synchronous ventricular contraction 
and done as the last resort in refractory heart failure patients and its efficiency 
has been demonstrated in CARE –HF (Cardiac Resynchronization in Heart 
Failure Study). Enzyme replacements and  gene therapy are evolving concepts 
which are impotents in related conditions. 
3)Heart failure with preserved ejection fraction : 
                                            Therapeutic end points in HFpEF patients are to 
relieve congestion, stabilization of blood pressure , control of heart rate and 
improving exercise tolerance. Various trials like CHARM and I-PRESERVE 
involving ARBs did not yield greater benefits. Novel therapy like sildenafil 
have proved less beneficial but an hybridized molecule of ARB with an 
endopeptidase inhibitor , LCZ696, enhances myocardial relaxation and 
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reduction in ventricular hypertrophy promising future evaluations and potential 
use in these subsets of patients. 
THE LIVER : 
                                          The liver is an important solid organ in the abdomen 
with variety of functions which include the synthetic, digestive, detoxifying, 
maintaining blood hemostasis , storing of blood as well as micronutrients etc. In  
the adult life though the liver receives blood supply from that the portal vein 
comprising of more than 80% and the remaining 20% from the systemic 
circulation ,namely, the hepatic artery and drained by hepatic veins into the 
systemic circulation. The portal vein is formed by the joining of the splenic vein 
draining the spleen and greater curvature of the stomach with that of the 
superior mesenteric artery which drains the small intestine and colon . The 
hepatic artery  arises from the celiac trunk dividing into the right and left artery 
while sending of a cystic artery branch also. The hepatic veins are usually 3 in 
number while there can be many anatomical variation noticed in more than 30% 
of individuals. 
                                     The portal flow is interconnected with the systemic 
circulation because the draining of blood from gut which consists of the 
nutrients  that were absorbed  is mainly due to blood supply from the systemic 
arteries . Since there are connections between portal and systemic circulation in 
the areas like paraumblical, bare area of liver ,retroperitoneal, rectal and lower 
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end of esophagus there always exists a bypass for portal blood to enter into the 
systemic circulation without involving the liver. The hepatic excretion of bile is 
through the biliary system which comprises of intra as well as extrahepatic 
ducts with the cystic duct where the bile drains ultimately into the second part 
of duodenum. The hepatic microanatomy consists of the sinusoids arranged in 
pentagonal patterns within the liver with the central vein and portal triads. 
Rappaport classification details about 3 zones of hepatic acini ( 5): 
                     Zone 1: around the portal triad, where the nutrient and oxygen 
content is more due to mixing of blood in sinusoids 
                    Zone 2: the middle zone 
                   Zone 3: the most prone area foe ischemia surrounding the central 
vein and hence important in hypoperfusion injuries. 
                                The arterial flow is inversely related to portal flow probably 
due to the mechanism of hepatic arterial buffer response based on washout of 
locally produced adenosine. This molecule adenosine secretion and 
concentration is influenced by hepatic lobular blood flow acting by release of 
nitrous acid and also experimental models have shown that infusion of 
adenosine have reduced ischemic liver injuries. 
CIRCULATION AND LIVER (4): 
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                            The response to circulatory dysfunction , be it congestive or 
ischemic ,there occurs typical histological and biochemical abnormalities. When 
the ischemic state  do affect the liver cells it is more so in the zone 3 perivenular 
region which resolves spontaneously when there is reperfusion. The 
biochemical changes occur in form of drastic and enormous elevation of the 
hepatic liver enzymes, namely, AST and ALT along with increase in serum 
bilirubin also. These abnormalities can depend upon the time duration of disease 
state, liver condition and the associated drug related liver toxicity. This liver 
dysfunction is also noticed with passive congestion whose pathophysiology and 
features are to be discussed below. 
                            The main disease states that can cause defects in the hepatic 
circulation and thereby disease state are left and right ventricular failure 
,ischemic cholangiopathy, valvular heart disease, constrictive pericarditis, heat 
stroke, hepatic infarction. Other processes that can affect liver biochemistry are 
sepsis, venous thrombosis and vasculitis etc. These effects are more pronounced 
with that of hepatic arterial obstruction since it supplies singularly the bile 
ducts, both intra as well as extrahepatic . Hepatic infarction that occurs with that 
of  hypoperfusion results in infarction at all levels ,segmental, subsegmental and 
lobar. 
ISCHEMIC HEPATITIS: 
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                                    Ischemic hepatitis signifies deceased oxygen delivery due 
to systemic  hypotension and also cardiac pump failure leading onto global  
hypoperfusion. Hepatic blood decreases to an extent of 10% when the blood 
pressure falls  by 10 mm Hg  and will not be injurious in normal persons due to 
compensatory mechanisms that come into play during circulatory failure.This 
pump failure as earlier discussed can occur due to result of myocardial 
infarction, congestive heart failure, massive pulmonary embolism, septic shock, 
heat stroke, dehydration and also hypovolemia due to massive bleed. Shock 
liver is specific term used when there is shock related effect.  
                                         The pathological basis behind ischemic hepatitis is 
different since inflammation is not a hallmark of this .The specific feature that is 
present is the zone 3 necrosis with a highly variable lobular collapse which 
could vary depending upon the the duration and the severity of the insulting 
process. In cases of right ventricular acute infarction, the liver histology shows 
features of both congestive and ischemic hepatitis characteristics. These 
microscopic alterations in the histology resolve spontaneously over a given 
period of time and then liver continues to regenerate except in persons having 
co morbid liver illness where the changes tend to stay or recur. 
                                     The important feature of ischemic hepatitis or acute 
cardiogenic liver injury (ACLI) is the enormous elevation the hepatic enzymes, 
namely, the aminotransferases and lactate dehydrogenase (LDH). The increase 
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occurs in 24 -48 hrs with the development of circulatory failure and this feature 
resolves in 4 to 7 days if the hypotension has been treated properly. The 
elevation that occurs can be in the range of 1000 IU/litre and easily picked up 
owing to complete screening of the acutely ill patient. The rise in LDH parallels 
that of alanine transaminases (ALT) and usually ALT/LDH ration is within the 
1.5 range. This rise in serum transaminases also can occur in toxic as well as 
infectious hepatitis but can be differentiated with the  speedy recovery of 
transaminases to normal level in ischemic hepatitis as well as clinical features of 
viral infections. Ischemic hepatitis is also associated with rise in renal function 
tests values since the same circulatory failure affects the kidneys while other 
causes of transaminases elevation don’t see the same.  
                                     Serum bilirubin will continue to rise after the elevation 
of the transaminases and will peak around 3-4 days . This rise in serum bilirubin 
values is greatly influenced by the associated co morbid illness of the liver in 
particular and the hemodynamic status of the patients in general. The other tests 
that can be abnormal are that of  Prothrombin time where the international 
normalized ratio (INR) can be increased mildly and also resolves with vitamin 
K support to the liver. The variations in serum ammonia level in ACLI is not 
much so as to cause encephalopathy which can other wise be caused by 
circulatory failure leading onto hypoxic brain damage.  
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                                      The pattern of elevation in enzymes can occur with 
subclinical effects of hypotension which can incite the liver injury  commonly 
seen in patients with chronic heart failure both systolic and diastolic . Seeto et 
al.(9) found that hypotension alone did not induce acute liver injury. Patients 
with ACLI were compared with a control group comprising trauma victims who 
had evidence of prolonged hypotension . Henrion et al. (8) examined ACLI in 
patients admitted to the coronary intensive care unit with evidence of low 
cardiac output. Patients with biochemical evidence of cardiogenic injury had 
significantly higher central venous pressures compared to patients who had low 
cardiac output but no ACLI. The cirrhotic patients developing hypotension and 
ischemic hepatitis have mortality in excess of 60-70% even with  advanced 
hospital care. 
 
                                    The treatment of ischemic hepatitis starts with the 
correction of circulatory failure and reverting back to normal hemodynamics. 
Some trial studies have been undertaken but a set protocol or drug therapy has 
not been devised to treat this condition. Dopamine infusion in one study has 
tried in which it improved hepatic blood flow but the benefits of hepatic 
recovery could not be noticed . Adenosine as discussed earlier may be involved 
in hepatic buffering system but this drug has been utilized only in animals while 
in humans only to prevent reperfusion injury after live donor graft. 
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Histology slides: 
A) changes with ACLI-original magnification *4 
B) original magnification *20-Pattern of hepatocyte loss is consistent 
with ischemic injury. Hepatocytes have completely disappeared , leaving 
a loose reticular framework while there is no regenerative collagen 
activity 
C) Masson trichrome stain, original magnification*10 thereby suggesting 
a fairly recent event. The presence of mild ductular changes including 
ductular proliferation, occasional neutrophils associated with ductules, 
and ductular bile stasis are likely secondary to the ischemic event 
D) Changes consistent with chronic hepatic passive congestion, in a 
patient with chronic HF . There is minimal inflammation in the portal 
areas, and no interface activity is evident. Only 1 focus of canalicular 
cholestasis is seen. Extensive spidery and dense perivenular fibrosis 
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exists; this extends into the lobule and bridges (stage 3) with other 
central, and focally, portal areas 
 E) Masson trichrome stain (original magnification *10) highlights the 
extensive nature of zone 3 (central) fibrosis. Some of the perisinusoidal 
hepatic plates are atrophic and attenuate 
HEPATIC INFARCTION: 
                   This is the most severe form of hepatic ischemia wherein there is 
total occlusion of blood supply at level of lobar,segmental or subsegmental 
leading onto coagulative necrosis. The only mode of healing in this processs is 
through fibrosis and scar formation. The severity of hepatic dysfunction appears 
mainly with relation to the artery occlude, if it is at level of branches of hepatic 
artery affecting only the subsegmental level the hepatic enzyme abnormalities 
are limited. Hepatic infarction occurring solely with cardiac failure are rare. 
ISCHEMIC CHOLANGIOPATHY: 
                    The bile duct as discussed earlier has the lone blood supply from 
the hepatic arteries only. Hence any abnormality in the hepatic blood flow can 
resulting from embolism,injury during surgery and hypotension resulting in 
circulatory failure can cause necrosis in the bile duct epithelium along with that 
of ischemic hepatitis. There occurs elevation alkaline phosphatase and gamma 
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glutamyl transferase enzyme elevation more than the transaminases if there is 
no associated ischemic hepatitis. 
HEAT STROKE: 
                 Heat stroke is very fatal condition affecting the whole body systems 
and fatality rates can reach upto 25-30%. The liver bears the brunt more in this 
condition since it is affected in two ways: hepatic necrosis due to elevated core 
body temperatre and also the associated hypotension. The liver enzymes are 
elevated with the elevation in AST being more than that of ALT . This happens 
because of the elevation in the other isoenzyme forms from brain,muscle, 
kidney. The recovery these enzymes takes much longer time than the ischemic 
hepatitis – over weeks . Bad prognostic indiactors are enormous elevationof 
enzymes as well as progressive rise in serum bilirubin.the histolgic picture 
includes that of zone 3 necrosis,steatosis,sinusoidal dilatation and cholangiolar 
proliferation. 
PASSIVE CONGESTION: 
                             Passive congestion occurs in individuals with isolated right 
heart failre, biventricular failure, cor pulmonale, chronic pulmonary embolism, 
valvular heart diseases,constrictive pericarditis. The histopathologic description 
of the liver in state of chronic congestion will be ; reddish central areas 
corresponding to central vein congestion and hemorrhage into zone 3 
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,surrounded by pale or yellowish areas of zone 1 or 2 with fatty changes, 
fibrosis around the central vein is seen and over course of time this fibrosis will 
become as a bridging fibrosis leading onto cirrhotic liver. Usually other types of 
cirrhosis have portal to portal fibrosis and also the hepatocytes around the portal 
regions may regenerate to form small nodules .The pathological alterations lead 
onto produce cardiac cirrhosis and high protein ascites. This ascites is formed 
due to the chronic congestion which causes the sinusoidal enlargement, space of  
Disse enlargement and collection of fluid thereby seeping into the peritoneal 
cavity forming ascites. This congestion also causes sinusoidal fibrosis 
preventing diffusion of oxygen and nutrients leading onto increased 
susceptibility of zone 3 necrosis of hepatocytes. Studies have proven that even 
though the patho- physiologic alterations can lead onto liver related mortality ,it 
is usually associated with left ventricular damage. 
                            There are 3 ways of presentation in patients with passive 
congestion of liver : 
1) Asymptomatic with mild elevation in serum bilirubin, INR and liver 
enzymes, 
2) Dull right upper quadrant pain, 
3) For evaluation of ascites 
                            The common physical findings present are that of right 
ventricular failure like elevated Jugular Venous pressure, hepatojugular reflex, 
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hepatomegaly which will be tender, pulsations in the enlarged liver if tricuspid 
valvular abnormalities are present and also pedal edema. 
                             The biochemical alterations in the passive congested state are 
mainly a mild elevation in the enzymes,  serum bilirubin but these can be 
normal also. Serum biliribin elevation is frequently due to the unconjugated 
fraction and it is proven that the elevation parallels the severity of congestion 
and right atrial pressure elevation. Maximum value that can be attained is 20 
mg/dl with severe congestion. Serum albumin level is typically normal or may 
be reduced to some extent. Prolongation of Prothrombin time is the most 
consistent alteration that take place in congested state and it resolves with that 
of reverting to normal circulatory state. Serum ammonia levels may be 
increased and all of these abnormalities tend to increase when there is 
associated left ventricular dysfunction. 
                                  Ascites is a frequent finding and it tends to be high protein 
fluid with the serum ascetic fluid albumin gradient more than 1.1 or ascetic fluid 
albumin more than 2.5 gm%. Another feature differentiating passive congestion 
induced ascites and liver disorder is the elevated free and wedged  hepatic 
venous pressure with normal hepatic venous pressure gradient(HVPG). Patients 
with chronic passive congestion have relatively stable hepatic functions as 
compared to the patients with left heart disease which will affect the hepatic 
perfusion. 
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                                        Treatment of this passive congestion is correction of 
underlying cardiac condition and also improving the forward cardiac ouput. 
Ascites is treated with diuretics taking care in preventing  treatment and 
dehydration with large ascites being treated with paracentesis and surgical 
stenting procedures.  
CONSTRICTIVE PERICARDITIS: 
                               Constrictive pericarditis presents itself similar to that of the 
Budd Chiari syndrome where it will be associated with marked elevation of the 
central venous pressure which can cause zone 3 hepatic necrosis. The enzyme 
elevation and other biochemical abnormalities occur at much rapid rate than 
other forms of passive congestion. Eventhough there is elevation of enzymes , 
the increase in serum  bilirubin is not seen as much. Pericardectomy can relieve 
the symptoms and can cause reversion of liver biochemistry. 
LIVER BIOCHEMISTRY  
ENZYMES THAT SERVE AS THE INDICATORS OF HEPATOCELLULAR 
NECROSIS 
AMINOTRANSFERASES:  
    In cases of acute hepatocellular injury such as hepatitis, 
serum  transaminases serve as the most useful markers of the liver cell injury 
Quantifying the formation of pyruvate and oxaloacetate which are the products of 
the aminotransferase reaction to their enzymatic reduction to lactate and malate is 
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one of the several techniques used for assessing the activities of ALT and AST in 
serum. Nicotinamide adenine dinulcleotide is formed as a result of the oxidation 
of the reduced form of nicotinamide adenine dinucleotide which in turn is the 
cofactor in this reduction reaction. This process can be easily found out by 
spectrophotometer as NADH losses its potential to absorb light at 340nm on 
conversion. 
                               As per descending order of concentration AST is found in 
the liver, cardiac muscle, skeletal muscle, the kidneys, the brain, pancreas, the 
lungs, leukocytes and erythrocytes. On the other hand liver has the maximum 
levels of ALT. On the event of destruction of the tissues or due to permeability 
changes in the membrane the serum transaminases tend to increase. When 
aminotransferases are injected they get equally dispersed in interstitial fluid and in 
plasma from where they get broken down down by reticuloendothelial cells and 
are thus cleared off similar to other serum proteins. In this process AST is quickly 
metabolized than ALT and the hepatic sinusoidal cells are the main stay for AST 
clearance. Both biliary and urinary excretion do not account for ALT or AST 
clearance as there is no aminotransferases found in urine and only very minute 
quantities are being found in bile. 
  Pyridoxal 5’-phosphate serves as the cofactor for both ALT and AST and 
these transaminases exists in both apoenzyme and holoenzyme forms in serum. 
The site of existence of these  transferases vary in tissues, as ALT exists only in 
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the cytosol while AST exists both in cytosol and in mitochondria. Both the forms 
of AST are true isoenzymes are deemed to be immunologically separate. By 
processes such as immunoprecipitation, chromatography and electrophoresis the 
two forms can be separated.The mitochondrial isoenzyme of AST contribute to 
80%  its activity in liver while the cytosolic isoenzyme remains as the major 
contributor to the circulating AST activity. The isoenzyme analysis of serum ALT 
and AST is hardly useful as they are not tissue specific except in patients with 
acute myocardial infarction or with chronic alcoholic liver disease. This is 
because, in myocardial infarction as an outcome of extreme tissue necrosis 
mitochondrial AST levels tend to increase and can be used as an indicator of the 
disease. The same happens in case of chronic alcoholic liver disease but not in 
acute alcoholic states. 
  Elevation of aminotransferases is noted in various conditions such 
as acute and chronic hepatitis, cirrhosis, infectious mononucleosis, heart failure, 
metastaic carcinoma, various infections and in some granulomatous liver 
disorders. Yet the peak elevations can be noticed in cases of extensive liver injury 
as in drug or viral hepatitis, in carbon tetrachloride or phaloidin (hepatotoxins) 
induced hepatotoxicity.In common , the levels increase in the low thousand. It is 
usually less than 300IU in alcoholic liver disease, and is rarely more than 500IU 
in conditions such as cirrhosis, obstructive jaundice, viral hepatitis in patients 
with immunodeficiency syndromes. When  these levels go high as 10000 
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to15000IU/L the recovery is seldom good. Both ALT and AST are 
simultaneously increases in cases of hepatobiliary diseases with the ALT levels a 
little greater than the AST levels. In conducting epidemiological studies regarding 
viral hepatitis, ALT is used as a sensitive and specific indicator than AST levels. 
  Numerous queries have risen regarding the normal range of ALT 
values which was previously set in 1950’s and has seldom changed then. Finally 
the normal range was the mean of values from a group of healthy individuals +/- 
2SD. This would have led to a wrong interpretation of the data. Thus, the upper 
normal values were decreased to 3U/L for men and 19U/L for women, which in 
turn resulted in a drop in specificity from 97.4% to 88.5% and an increase in 
sensitivity from 55% to 76.3% in detecting hepatitis c viremia patients. The 
elevation of serum transaminases is a poor guide which has got very little 
correspondence to the extent of liver cell injury. The result of acute hepatocellular 
diseases is defectively portrayed by absolute elevation of aminotransferases. The 
random decrease in serum aminotransferase levels though indicates recovery 
from the disease on one hand; it also serves as a poor prognostic sign in massive 
destruction of liver cells as in fulminant hepatitis due to loss of viable 
hepatocytes.  
  Even in the early phases of hepatitis, elevation in serum 
transaminases is noted even before the rise of serum bilirubin levels. Hence a 
decreasing trend in aminotransferase levels is noted while there is an increasing 
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trend in bilirubin levels. This decrease is particularly noted in recovery stage of 
viral hepatitis. During the development of chronic hepatitis or in cases of 
recrudescence of acute hepatitis a secondary rise or a persistent elevation is noted. 
Both ALT and AST levels show variability in instance of infections such as 
Hepatitis C. The constant elevation in aminotransferases is most often noted with 
patients with chronic hepatitis as their liver biopsy feature. While on the other 
hand normal ALT and AST levels coupled with Hepatitis C infection also elicits 
chronic hepatitis a s the liver biopsy feature. Thus, the serial assessment of the 
levels of aminotransferases serve as useful tool in determining the clinical stage 
of hepatitis and also in measuring the response to immunosuppressive therapy 
given in cases of chronic hepatitis.  
  The significance of AST/ALT ratio is very little when used for 
differentiating the various causes of hepatobiliary diseases. Yet, it is still a 
sensitive indicator in alcoholic liver disease in which the ALT level is not more 
than 300IU and AST/ALT ratio is more than 2. When the ratio is more than 3 
then it strongly suggests alcoholic liver disease. This is because ALT requires 
pyridoxal 5’ phosphate for its synthesis much more than AST. This is reduced in 
alcoholics and hence the altered AST/ALT ratio in the liver is reflected in the 
serum ratio as well. The increase in ALT and AST levels is usually not more than 
200IU and 300IU respectively in alcoholic liver disease. This is not properly 
substantiated by the reason that the hepatic concentrations are low. In alcoholic 
52 
 
liver disease associated with other states such as heart failure, drug toxicity the 
levels peak high to the range of thousands. In spite of which the AST/ALT ratio 
remains increased and is the outstanding feature of alcoholic liver disease.  
  The AST/ALT ratio has also been used in the study of chronic 
hepatitis C infection in which the ratio was used as a noninvasive marker of 
cirrhosis. The test revealed that cirrhosis developed when AST/ ALT ratio was 
greater than 1. The study had a higher specificity of (94%-100%) in spite of low 
sensitivity (44%-75%). This ratio existed because of the point that in cirrhosis 
patients the functional hepatic blood flow would get decreased, hence the 
uptake of AST by the hepatic sinusoids would have got decreased and thus this 
gets reflected as a rise in serum AST levels.  
    Increased levels of serum transaminases are not 
considered as pointers to hepatobiliary diseases. Even in other occasions, such 
as myocardial infarction where severe cardiac muscle damage occurs or in cases 
of skeletal muscle damage, the AST levels get elevated. On the other hand 
increase in ALT occurs in cardiac disease. This is seen in patients with large 
infarcts with congestive heart failure and circulatory collapse which would lead 
to hepatic ischemia and central hepatocellular necrosis resulting in release of 
ALT (hepatic origin).  
  In the instance of muscle disease increase in ALT and AST levels 
is noted. Yet the increase is usually less than 300U/L and rarely exceeds this 
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range except in cases of acute rhabdomyolysis. Rise in AST and ALT levels has 
also been recorded in persons doing vigorous exercise at the time of which the 
AST/ALT ratio initially is about 3:1 but then decrease to 1:1 owing to the short 
half life of AST. Similarly the ratio is around 1:1 in patients with chronic 
muscle disease.When old calorimetric tests are done drugs such as erythromycin 
or paraaminosalycylic acid can produce false elevation in aminotransferases. 
One such special situation is uremia, in which a low level of aminotransferases 
(AST) is seen. Once after dialysis the level of AST starts to rise up. This has 
brought out that a dialyzable inhibitor of aminotransferase reaction is present in 
uremic patients. 
ISOCITRATE DEHYDROGENASE: 
  A cytoplasmic enzyme which is found in liver heart, kidneys, and 
skeletal muscle is Isocitrate dehydrogenase. This is a less sensitive indicator in 
acute and chronic hepatitis whose activity matches that of aminotransferases 
when through serum levels. As like glutamate dehydrogenase, isocitrate 
dehydrogenase is also a marker of centrilobular zone necrosis. This enzyme is 
also found to rise in conditions of disseminated malignant diseases in spite of 
normal liver functions. ICDH measurements in serum have shown no greater 
advantage than the measurements of aminotransferases in spite of its promotion 
asa marker of liver disease. 
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LACTATE DEHYDROGENASE: 
  Lactate dehydrogenase is an enzyme which is known to 
originate from tissues all over the body. It is a cytoplasmic enzyme and has got 5 
isoenzymes in serum. By electrophoresis these isoenzymes are easily separated 
and the slowest moving isoenzyme is found in the liver. It is deemed as a useful 
indicator of myocardial infarction and hemolysis. In case of liver disease this 
enzyme has got poor specificity and sensitivity, even when its particular 
isoenzymes are assayed.  
ENZYMES USED IN THE DETECTION OF CHOLESTASIS 
ALKALINE PHOSPHATASE:  
                 Though found in numerous sites all through the 
body such as bone osteoblasts, the canalicular membranes of hepatocytes, the 
brush border of the mucosal cells of the small intestine, the placenta, the white 
blood cells and the proximal convoluted tubules of the kidneys, the accurate 
function of this enzymes is not known. The alkaline phosphatase was known 
play an active role in rat liver by downregulating the secretion of intrahepatic 
biliary epithelium. Also it was found to be related to calcification of bones. 
Despite this its particular functions could not be demonstrated though at many 
sites it is said to involve in transport processes. The serum levels of alkaline 
phosphatase reflect its activity. The source of alkaline phosphatase is mainly 
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derived from three sites- the liver, bone and the intestinal tract (rarely) of which 
the liver and the bone stand out to be important sources. When infused, the 
alkaline phosphatase had a half-life of 7 days and was found that it also behaves 
similar to other serum proteins. The site of destruction of these enzymes is not 
known but its clearance was found to be independent of the patency of the bile 
ducts and of the functional status of the liver.         
  Various procedures are used to measure the alkaline 
phosphatase activity. Using -nitrophenylphosphate as substrate and an amino 
alcohol (2-amino-2-methyl-1-propanol) as a buffer a procedure is done in which 
the rate of release of -nitrophenol or phosphate is measured in the presence of 
specified incubation conditions. The activity of alkaline phosphatase that 
produces 1mmol of chromogen or inorganic phosphate per minute is defined as 
international units in which alkaline phosphatases levels are expressed. 
Numerous clinical diseases could be detected by way of the results obtained by 
the above procedures. Alkaline phosphatase has a variety of isoenzymes hence 
the reaction of these enzymes are different in different assay systems. So even if 
a conversion factor is used to interchange the values obtained by different 
procedures the resultant correlation between these values is very poor in any 
individual. Thus by expressing the results obtained as multiples of the upper 
limit of normal the results could be compared. The concentration of phosphate, 
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citrate, and magnesium and the type and concentration of the buffer has got 
significance as numerous analytic sources of error can occur. 
                           When the mean alkaline phosphatase levels are 
measured, it is found to be a little higher in men when compared to the women 
individuals in the age group of 15- 50 years. While the levels are found 
somewhat equal in both men and women in people more than 60 years of age 
and are also a little higher than compared to that of younger individuals. This 
variation can never be explained. In young children due to growth of bones there 
is an influx of enzymes from osteoid tissues resulting in elevated levels of 
alkaline phosphatase and is equal in both the sexes. Even in the absence of 
hepatobiliary diseases the levels of alkaline phosphatase can reach upto three 
times that of an adult in case of a healthy adolescent individual. In normal 
pregnancy the levels are found to double due to the inputs from that of placental 
phosphates.  
                                                 Physiologically the levels of alkaline phosphatase 
is high during growth and in pregnancy. Pathologically elevations can occur in 
bone diseases due to active osteoblasts as that of elevations seen in hepatobiliary 
diseases. Elevations in alkaline phosphatase are seldom caused by the intestinal 
tract and the kidneys.   
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Gamma glutamyl transpeptidase : (GGT) 
                              GGT is present in the liver, spleen, heart, brain, kidneys and 
vesicles being present in normal serum. Elevated GGT levels are seen in diseases 
of liver,biliary tract and pancreas which are usually correlate with the alkaline 
phosphatase levels.GGT levels are useful because they are not related to any 
bone diasease and are high in alcoholic liver diseases when other enzymes are 
normal.GGT levels easily correlate with severity of alcoholic hepatitis than 
others.GGT levels confer specificity to liver when ALP is elevated . 
Serum albumin : 
                               Average adult albumin levels vary from 300 to 500 gram 
synthesized by liver.The rate of synthesis depends upon the loss or decrease due 
to dilution in disease states and regulated by nutritional status, osmotic pressure, 
systemic inflammation and hormone levels. It’s synthesis is stimulated by 
aminoacids like tryptophan, arginine,ornithine, corticosteroids,thyroxine and 
urea synthesis while alchol decreases its synthesis.Levels less than 3gram % 
should arise suspicion of chronic hepatitis and also ischemic hepatitis. 
Prothrombin Time : 
                             Clotting is a complex mechanism which involves various 
factors like Factor II,VII,IX,X requiring Vitamin K   for the synthesis by the 
liver. The Vitamin K dependent gamma carboxylation of the factors are 
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deranged in hepatic disorders releasing abnormal Prothrombin in the 
circulation.This abnormal Prothrombin levels can be useful even in absence of 
prolongation of the PT-INR ratios. Hypovitaminosis K can be present in the 
obstructive hepatic states,deficiency in diets,antibiotics intake and parenchymal 
liver diseases. PT-INR elevation has significant prognostic values in terms of 
acute hepatic decompensation  and the improvement of atleast  30%  in values 
shows that the parenchymal function is good. 
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                                                     This study on the prevalence and assessment of 
individual tests of the liver function tests in the heart failure patients was done 
in the department of medicine, Tirunelveli medical college from may of 2016 to 
the the june of 2017 with the help of various departments like cardiology 
,radiology and laboratory support. The precise reason of the study was to prove 
the alterations in liver functions which happens with various forms of heart 
failure and to use the results to assess,correlate with the severity of heart failure  
leading  onto the easy prediction of severity of heart failure   using liver 
function tests along with the clinical features even in absence of 
echocardiographic assessment. 
                                                   This study was done with the consent of 50 
people who were suffering from heart failure selected with the help of 
Framingham criteria for diagnosis of heart failure and also divide with help of 
echocardiographic assessment into two sets of patients ,namely, one with 
reduced ejection fraction (<40%) and next with preserved ejection fraction 
(>40%). All the required approval were sought and bought from the concerned 
departments along with the ethical approval from the respective college ethical 
committee and proceeded. The patients were taken up for study after doing the 
required laboratory and radiological assessment including ultrasound abdomen , 
echocardiogram (ejection fraction and diastolic dysfunction grading) after strict 
adherence to the inclusion and exclusion criteria.  An oral consent was obtained 
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from patients and also attenders in case the patient was obtunded during the 
study, after explaining to them the nature of the study which does not interfere 
with management of the patient. 
INCLUSION CRITERIA: 
                         Acute heart failure 
                         Chronic heart failure 
EXCLUSION CRITERIA: 
                         Primary liver disease including infective liver diseases 
                         Cirrhotic patients 
                         Malignancy 
                        Alcoholics 
 A patients were first asked about the personal details and 
then were asked about the specific symptoms of dyspnoea,orthopnoea, 
PND,chest pain.fatiguability,exercise intolerance ,ankle 
edema,jaundice,abdominal distension ,dilated neck veins and night coughs.they 
were enquired about their previous hospitalizations, drug intake,liver diaseases, 
blood transfusions, STD  diseases history ,alcoholism and  treatment history if 
any. 
                                      Then the patient was examined for elevation in jugular 
venous pressure, low blood pressure,tachycardia  along with the routine general 
examination .the cardiovascular system examination was done carefully to look 
for signs of left as well right ventricular failure and if so they were included in 
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this study. Other system examination included looking for congestive liver 
enlargement, pleural effusion along with the routine . 
                                  Laboratory evaluations were done with normal routine 
investigations of complete hemogram, urine routine tests, renal function and 
special emphasis was laid on liver function tests with the all the components of 
LFT done along with the screening for hepatitis and HIV. Serum enzymes like 
AST, ALT, ALP, GGT levels were taken as elevated when exceeding the 4 
times the normal levels as explained in the review of literature above. 
Ultrasound abdomen was done for congestion of the liver while echocardiogram 
was done to diagnose the heart failure with reduced and preserved ejection 
fraction for classification along with assessment of diastolic dysfunction in 
terms of normally practiced grading of 1 to 4 using the tissue and pulse Doppler 
techniques in echocardiogram. 
                                The information collected regarding all the selected cases 
were recorded in a Master Chart. Data analysis was done with the help of 
computer programming using Epidemiological Information Package (EPI 2010) 
developed by Centre for Disease Control, Atlanta, USA. 
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GROUP STATISTICS 
     
  GROUP N Mean Std. Deviation P value 
AGE 
Group 1 32 58.91 11.13 
0.004 Group 2 18 67.67 7.40 
TOTAL 
BILIRUBIN 
Group 1 32 2.07 1.35 
0.186 Group 2 18 1.58 1.02 
INDIRECT 
BILIRUBIN 
Group 1 32 1.58 1.01 
0.05 Group 2 18 1.07 0.51 
DIRECT 
BILIRUBIN 
Group 1 32 0.48 0.40 
0.823 Group 2 18 0.51 0.53 
ALT 
Group 1 32 404.47 395.12 
0.003 Group 2 18 104.22 147.78 
AST 
Group 1 32 361.56 350.38 
0.004 Group 2 18 102.78 129.30 
GGT 
Group 1 32 122.31 152.11 
0.242 Group 2 18 181.56 197.74 
ALP 
Group 1 32 127.31 170.20 
0.378 Group 2 18 174.06 192.56 
ALBUMIN 
Group 1 32 3.35 0.77 
0.281 Group 2 18 3.57 0.40 
PT_INR 
Group 1 32 1.05 0.24 
0.971 Group 2 18 1.06 0.20 
EF Group 1 32 26.34 6.72 
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PART 1 
HEART FAILURE WITH REDUCED EJECTION FRACTION 
  Class N Mean Std. 
Deviation 
P value 
TOTAL 
BILIRUBIN 
2 6 1.47 1.34 0.212 
3 11 1.81 1.16 
4 15 2.50 1.42 
INDIRECT 
BILIRUBIN 
2 6 1.17 1.10 0.312 
3 11 1.43 0.92 
4 15 1.86 1.03 
DIRECT 
BILIRUBIN 
2 6 0.30 0.25 0.147 
3 11 0.38 0.36 
4 15 0.63 0.45 
ALT 2 6 50.00 6.07 <0.0001 
3 11 200.82 341.84 
4 15 695.60 291.48 
AST 2 6 45.00 3.79 <0.0001 
3 11 174.45 291.48 
4 15 625.40 257.11 
GGT 2 6 120.67 163.65 0.193 
3 11 59.18 6.78 
4 15 169.27 190.10 
ALP 2 6 114.33 146.88 0.132 
3 11 52.36 8.24 
4 15 187.47 219.15 
ALBUMIN 2 6 3.52 0.77 0.006 
3 11 3.85 0.61 
4 15 2.93 0.67 
PTINR 2 6 0.98 0.12 0.003 
3 11 0.90 0.06 
4 15 1.19 0.28 
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    Mean Standard. Deviation 
EF 26.34 6.72 
TOTBILIRUBIN 2.07 1.35 
INDIRECT BILIRUBIN 1.58 1.01 
DIRECT.BILIRUBIN 0.48 0.40 
ALT 404.47 395.12 
AST 361.56 350.38 
GGT 122.31 152.11 
ALP 127.31 170.20 
ALBUMIN 3.35 0.77 
PROTHROMBIN TIME-
INR 1.05 0.24 
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CORRELATION: 
A) NYHA CLASS VS TOTAL BILIRUBIN: 
 
NYHA CLASS 
TOTAL.BILIRUBIN  
Normal Elevated P value  
2 5 1  
 
0.197 
3 6 5 
4 6 9 
TOTAL 17 15 
 
 
 
B) NYHA CLASS VS LIVER FUNCTION TEST: 
 
LFT 
NYHA CLASS  
P value 2 3 4 
Normal 5 6 1  
0.002 Abnormal 1 5 14 
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C) NYHA CLASS VS INDIRECT BILIRUBIN 
 
NYHA CLASS 
INDIRECT.BILIRUBIN  
Normal Elevated P value 
2 5 1  
 
0.197 
3 6 5 
4 6 9 
 
 
 
D) NYHA CLASS VS DIRECT BILIRUBIN: 
 
NYHA CLASS 
DIRECT BILIRUBIN  
Normal Elevated P value 
B 5 1  
 
0.162 
C 7 4 
D 6 9 
TOTAL 18 14 
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E)NYHA CLASS VS ASPARTATE TRANSAMINASE: 
NYHA 
CLASS 
AST P value 
 Normal Elevated 
2 6 0  
<0.0001 
 
 
3 9 2 
4 1 14 
TOTAL 16 16 
 
 
F)NYHA CLASS VERSUS ALANINE TRANSAMINASE: 
NYHA 
CLASS 
ALT P value 
 Normal Elevated 
2 6 0  
 
<0.0001 
3 9 2 
4 1 14 
TOTAL 16 16 
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15
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CLASS
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G)NYHA CLASS VS ALKALINE PHOSPHATASE : 
NYHA 
CLASS 
ALP P value 
 Normal Elevated 
2 5 1 0.18 
3 11 0 
4 11 4 
TOTAL 27 5 
 
 
H)NYHA CLASS VS GAMMA GLUTAMYL TRANSFERASE: 
 
NYHA 
CLASS 
GGT P value 
Normal Elevated 
2 5 1  
 
0.18 
3 11 0 
4 11 4 
TOTAL 27 5 
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I) NYHA CLASS VS SERUM ALBUMIN : 
NYHA 
CLASS 
 
ALBUMIN P value 
Normal Elevated 
2 5 1  
 
0.002 
3 10 1 
4 4 11 
TOTAL 19 13 
 
 
J)NYHA CLASS VS PROTHROMBIN TIME: 
NYHA 
CLASS 
PTINR P value 
 Normal Elevated 
2 6 0  
 
0.006 
3 11 0 
4 8 7 
TOTAL 25 7 
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K) EJECTION FRACTION VS TOTAL BILIRUBIN: 
EJECTION 
FRACTION 
TOTAL BILIRUBIN P value 
Normal Elevated 
<20% 2 7  
 
0.028 
>20% 15 8 
TOTAL 17 15 
 
 
  
 
L) EJECTION FRACTION CORRELATION WITH ABNORMAL LFT: 
  EF vs LFT   
Correlations Pearson Correlation -0.569 
  P value  <0.0001 
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M) EJECTION FRACTION VS INDIRECT BILIRUBIN:  
 
EJECTION 
FRACTION 
INDIRECT BILIRUBIN P value 
Normal Elevated 
<20% 2 7  
0.028 >20% 15 8 
TOTAL 17 15 
 
 
 
N) EJECTION FRACTION VERSUS DIRECT BILIRUBIN: 
EJECTION 
FRACTION 
DIRECT BILIRUBIN  
P value Normal Elevated 
<20% 2 7  
0.015 >20% 16 7 
TOTAL 18 14 
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O) EJECTION FRACTION VS ALANINE TRANSAMINASE: 
EJECTION 
FRACTION 
ALT P value 
Normal Elevated 
<20% 0 9  
<0.0001 >20% 16 7 
TOTAL 16 16 
 
 
 
P) EJECTION FRACTION VS ASPARTATE TRANSAMINASE: 
EJECTION 
FRACTION 
AST P value 
Normal Elevated 
<20% 0 9  
<0.0001 >20% 16 7 
TOTAL 16 16 
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Q) EJECTION FRACTION VERSUS ALKALINE PHOSPHATASE: 
EJECTION 
FRACTION 
ALP  
P value Normal Elevated 
<20% 6 3  
0.084 >20% 21 2 
TOTAL 27 5 
 
 
 
 
R) EJECTION FRACTION VERSUS GAMMA GLUTAMYL 
TRANSFERASE: 
EJECTION 
FRACTION 
GGT  
Normal Elevated P value 
<20% 6 3 0.084 
>20% 21 2 
TOTAL 27 5  
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S)EJECTION FRACTION VS SERUM ALBUMIN: 
EJECTION 
FRACTION 
 
ALBUMIN P value 
Normal Elevated 
<20% 0 9  
<0.0001 >20% 19 4 
TOTAL 19 13 
   
 
 
T)EJECTION FRACTION VS PROTHROMBIN TIME: 
EJECTION 
FRACTION 
PT-INR P value 
Normal Elevated 
<20% 6 3  
0.327 >20% 19 4 
TOTAL 25 7 
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CORRELATION SIGNIFICANCEOF EACH 
UNITS EJECTION FRACTION 
TOTAL 
BILIRUBIN 
Pearson Correlation -0.40 
P value 0.024 
INDIRECT  
BILIRUBIN 
Pearson Correlation -0.37 
P value 0.036 
DIRECT 
BILIRUBIN 
Pearson Correlation -0.37 
P value 0.036 
ALT 
Pearson Correlation -0.77 
P value 0.000 
AST 
Pearson Correlation -0.77 
P value 0.000 
GGT 
Pearson Correlation -0.27 
P value 0.139 
ALP 
Pearson Correlation -0.28 
P value 0.115 
SERUM 
ALBUMIN 
Pearson Correlation 0.59 
P value 0.000 
PT-INR 
Pearson Correlation -0.30 
P value 0.097 
 
                    The Pearson correlation of negative values implies the negative 
correlation of two variables , for example , a value of  -0.77 of ALT enzyme 
explains that with decreasing ejection fraction there will  be elevation of ALT 
enzymes in HFrEF than ALP which has lesser correlation value of  -0.28. 
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PART -2 
HEART FAILURE WITH PRESERVED EJECTION FRACTION 
GROUP STATISTICS : 
      
 LFT 
NYHA 
CLASS N Mean 
Std. 
Deviation P value 
TOTAL.BILIRUBIN 
2 13 1.14 0.57 
0.004 3 4 2.60 1.24 
INDIRECT 
BILIRUBIN 
2 13 0.86 0.30 
0.012 3 4 1.50 0.64 
DIRECT 
BILIRUBIN 
2 13 0.28 0.28 
0.002 3 4 1.10 0.64 
ALT 
2 13 52.00 17.74 
0.048 3 4 196.50 259.50 
AST 
2 13 56.54 12.71 
0.044 3 4 182.50 223.17 
GGT 
2 13 63.38 13.44 
<0.0001 3 4 487.50 54.78 
ALP 
2 13 59.62 15.24 
<0.0001 3 4 470.00 69.82 
SERUM ALBUMIN 
2 13 3.69 0.26 
0.001 3 4 3.05 0.39 
PTINR 
2 13 0.99 0.10 
0.026 3 4 1.25 0.35 
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NYHA CLASS STATISTICS: 
1) NYHA CLASS VS LFT: 
 LFT 
  
CLASS P value  
2 3 4 
Normal 12 0 0 0.001 
Abnormal 1 4 1 
 
 
 
2) NYHA CLASS VS  TOTAL BILIRUBIN: 
CLASS TOTAL BILIRUBIN  
P value Normal Elevated 
2 12 1  
0.008 3&4 1 4 
TOTAL 13 5 
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3) NYHA CLASS VS INDIRECT BILIRUBIN: 
CLASS INDIRECT BILIRUBIN P value 
Normal Elevated 
2 12 1  
0.008 3&4 1 4 
TOTAL 13 5 
 
 
4) NYHA CLASS VS DIRECT BILIRUBIN: 
 
CLASS 
DIRECT BILIRUBIN  
P value Normal Elevated 
2 12 1  
0.008 3& 4 1 4 
TOTAL 13 5 
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5) NYHA CLASS VS ALT: 
 
CLASS 
ALT  
P value Normal Elevated 
2 13 0  
0.065 3&4 3 2 
TOTAL 16 2 
 
 
 
6) NYHA CLASS VS AST: 
CLASS AST  
P value Normal Elevated 
2 13 0  
0.065 3&4 3 2 
TOTAL 16 2 
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7) NYHA CLASS VS ALT:  
 CLASS ALP  P value  
Normal Elevated 
2 13 0  
<0.0001 3&4 0 5 
TOTAL 13 5 
 
 
 
8)NYHA CLASS VS GGT: 
CLASS GGT P value 
Normal Elevated 
2 13 0  
<0.0001 3&4 0 5 
TOTAL 13 5 
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9) NYHA CLASS VS SERUM ALBUMIN : 
CLASS ALBUMIN P value 
Normal Elevated 
2 13 0  
0.012 3&4 2 3 
TOTAL 15 3 
 
 
 
10) NYHA CLASS VS PROTHROMBIN TIME: 
CLASS PTINR  
P value Normal Elevated 
2 13 0  
0.065 3&4 3 2 
TOTAL 16 2 
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11) DIASTOLIC DYSFUNCTION GRADING VS LFT: 
GRADE 
 
LFT 
 
 
P value 
Normal Elevated 
2 12 1  
0.001 3 0 5 
TOTAL 12 6 
 
 
 
12) DIASTOLIC DYSFUNCTION VERSUS TOTAL BILIRUBIN: 
 
GRADE 
TOTAL BILIRUBIN  
P value Normal Elevated 
2 12 1  
0.008 
 
3 1 4 
TOTAL 13 5 
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13) DIASTOLIC DYSFUCNCTION VS INDIRECT BILIRUBIN: 
GRADE  INDIRECT BILIRUBIN P value  
Normal Elevated 
2 12 1  
0.008 
  
3 1 4 
TOTAL 13 5 
 
 
 
14) DIASTOLIC DYSFUNCTION VS DIRECT BILIRUBIN: 
GRADE DIRECT BILIRUBIN P value 
Normal Elevated 
2 12 1 0.008 
 3 1 4 
TOTAL 13 5 
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15) DIASTOLIC DYSFUNCTION VS ALT: 
 
GRADE 
 
ALT  
P value Normal Elevated 
2 13 0  
0.065 
 
3 3 2 
TOTAL 16 2 
 
 
 
16) DIASTOLIC DYSFUCTION VS AST: 
 
GRADE 
AST  
P value Normal Elevated 
2 13 0  
0.065 
 
3 3 2 
TOTAL 16 2 
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17) DIASTOLIC DYSFUNCTION VS ALKALINE PHOSPHATASE: 
 
GRADE 
ALP  
P value Normal Elevated 
2 13 0  
<0.0001 
 
3 0 5 
TOTAL 13 5 
 
 
 
18) DIASTOLIC DYSFUNCTION VS GAMMA GLUTAMYL 
TRANSFERASE: 
GRADE GGT  
P value Normal Elevated 
2 13 0  
<0.0001 
 
3 0 5 
TOTAL 13 5 
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19) DIASTOLIC DYSFUNCTION VS SERUM ALBUMIN: 
 
GRADE 
SERUM ALBUMIN  
P value Normal Elevated 
2 13 0  
0.012 
 
3 2 3 
TOTAL 15 3 
 
 
 
20) DIASTOLIC DYSFUNCTION VS PROTHROMBIN TIME:  
 
GRADE 
PT-INR 
 
 
P value 
Normal Elevated 
2 13 0  
0.065 
 
3 3 2 
TOTAL 16 2 
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                                 Heart failure and liver dysfunction occurring as a result of 
that is of prognostic significance and there are various studies which have been 
proceeded to prove that point both in acute decompensated and chronic heart 
failure. The cardio-hepatic interactions that lead onto abnormalities in the liver 
function tests in setting of  myocardial failure can be used as a corollary to 
understand  and  delineate the severity of heart failure ,thereby influencing the 
management aspect of the heart failure. 
                                  In this study, the study population was divided into two 
groups for sake of statistical analysis and disease pattern into: heart failure 
patient with reduced ejection fraction (HFrEF) and heart failure patient  with 
preserved ejection fraction(HFpEF). The most common etiology of HFpEF was 
hypertensive heart disease while that of  HFrEF was myocardial infarction 
followed by cardiomyopathies. Patients with myocarditis and valvular heart 
disease also presented with heart failure with reduced ejection fraction. One 
case of heat stroke also presented with severe myocardial depression with 
reduced ejection fraction. The general statistics showed that out of 50 patients, 
the patients with HFrEF were 32 and those with HFpEF were 18 in number. 
Although references suggest that the HFpEF  is  more  prevalent nowadays , in 
this study period many number of patients with HFpEF had to be excluded since 
they were alcoholic and possibly they would have been in NYHA class 1 
category not attending to the hospital settings in our region.  
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                                              The mean age of in HFrEF was 58.9 years while 
that of HFpEF was 67.6 years signifying the aging factor which is factor in the 
pathogenesis of HFpEF . The standard deviation with in both groups differed 
significantly with greater deviation of 11.13 in HFrEF group showing younger 
age of onset of HFrEF. There were specific predominance in female patients in 
HFpEF group while the first group did not show significant difference. Maria et 
al study had patients with an average age group of 66 yrs with no major 
deviation noticed in patients with acute heart failure (10). 
                    The HFrEF patients were divided according to the NYHA class and 
ejection fraction (EF) while the HFrEF were classified with help of NYHA class 
and also diastolic dysfunction grading which helped in correlating the severity 
of heart failure cases with the liver function abnormalities.  
                    In HFrEF patients, out of total 32 there were 6 patients in class II, 
11 patients in class III while 15 patients were in class IV heart failure. In 
HFpEF patients, out of 18 there were 13 patients in class II , 4 patients in class 
IV while a single patient presented with class IV heart failure symptoms. The 
prevalence of the abnormal LFT as a whole was present in 93 % of class IV, 83 
% of class III failure while only 20 % of class II patients had LFT abnormalities 
showing increased prevalence among severe clinical grading. Szygula 
Jurkiewicz et al demonstrated elevated LFT values in NYHA class II/3 
hypertensive patients was associated with higher mortality rates(11). Shingawa et 
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al (12) also showed the association of prognostic significance of elevated LFT 
with increased morbidity of heart failure patients.  In relation to ejection 
fraction compared with LFT, there was was excellent correlation with LFT 
abnormalities and decreasing ejection fraction with all 10 patients with less than 
20% EF having elevated values while patients with 20-40% EF having 45 % of 
abnormal values. 
                                          The individual elevation of serum bilirubin in HFrEF 
group was 16% in NYHA class II, 45% in NYHA class III, 60% patient in 
NYHA class IV while 77 % of patients with ejection fraction <20% had 77 % 
elevation and patients with >20% having 34% elevation. All these abnormalities 
were mainly due to the relative elevation of unconjugated bilirubin values in 
proportion with conjugated bilirubin. Shinwaga et al showed higher (64%) 
prevalence of bilirubin abnormality compared to Lau et al(19%) (13) and 
CHARM trial (14). 
                                             In HFpEF patients, the prevalence of  LFT 
abnormalities were only 6% in class II and it was around 80% in class III & IV 
pateints. The total prevalence of LFT abnormalities was 62.5 % indicating the 
prominence of LFT in heart failure. With diastolic dysfunction grading, grade 2 
patients had less than 10 %  while  grade 3 patients all were having elevated 
LFT values. The elevation of serum bilirubin was 8% in NYHA class 1 while it 
was 80% in severe classes. The grade 2 diastolic dysfunction was associated 
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with the same with 8% in grade 2 and 80% in grade 3&4. This rise is 
proportionately more in the conjugated bilirubin than the unconjugated fraction 
revealing prevalence of cholestatic pattern in HFpEF patients rather than the 
unconjugated pattern in HFrEF patients. The rise in bilirubin has been 
associated as an important prognostic indication as well as severity indicator (14). 
Single-center studies have shown higher mortality  rates , cardiac 
transplantation, and HF rehospitalizations in 
patients with increased plasma bilirubin .(16,17)   
                                        With respect to liver enzymes in the HFrEF patients , 
there was elevation in AST and ALT concomitantly with all patients with 
ejection fraction of <20% having elevated values and people with more than 
20% ejection fraction having prevalence of only 30 %. Patients with NYHA 
class II had 20 %, class III had no elevation and class IV had 26 % elevation. 
This rise in enzymes can be attributed with to ischemic liver injury caused by 
hypoperfusion of liver. In HFpEF , the rise in liver enzymes were subdued with 
no elevation in class II patients while 2 out of 3 in class III developed 
transaminitis which was same with grade 2 and 3 diastolic dysfunction 
respectively indicating less of the hepatocyte damage with ejection fraction 
being preserved . Mattews et al  (15)proved that AST along with serum bilirubin 
rise was independent marker of right ventricular failure  
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                                    The enzymes relating to cholestasis such as ALT and 
GGT were only elevated in 15 % of patients with HFrEF, more so only in 
severely decompensated patients like class III & 4 failure and ejection fraction 
of less than 20%. In patients with HFpEF, the elevation was present in  one 
third of the patient studied implicating the prevalence of cholestatic pattern 
more in cases of heart failure with preserved ejection fraction. Richman et al (19) 
proved  this cholestatic pattern may be due to congestive hepatopathy in HFpEF 
leading onto increased hepatic venous pressure causing intrahepatic small 
biliary radicles obstruction and also bile thrombi (15). Poelzl et al. (17) proved that 
serum GGT signifies independently prognostic information for  established 
clinical and biochemical markers , ischemic etiology, NYHA functional class, 
and hear failure markers such as N-terminal pro–B-type natriuretic peptide. 
Ruttmann et al. (18) showed that GGT to be a prognostic indicator of death 
including all cause mortality,incident heart failure indicating that GGT shows 
promise as a marker for subclinical or early stage disease. 
                                  With respect to the serum albumin , hypoalbunemia was 
present in 40 % of HFrEF group with the 16 % in NYHA class II and 73 % of 
class IV patients. With relation to ejection fraction , the lower (EF<20%) group 
had nearly 100 %  hypoalbuminnemia while only 17 % had in group with higher 
ejection fraction. In patients with HFpEF , there was reduction only with 60% 
of NYHA class III patients and grade 3 diastolic dysfunction patients . The 
reduction has been attributed to the nutritional status (20,21) with other factors 
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such as hemodilution (22) and inflammation playing their own part (23). Horwich 
et al. (23) demonstrated that hypoalbuminemia greatly increased the all-cause 
mortality, progressive heart failure , and increased risk of  transplantation in a 
set of patients with NYHA class III/IV symptoms. Low albumin levels also 
have been found to have prognostic value in patients with acute decompensated 
HF after adjustment for multiple prognostic variables, including N-terminal 
pro–B-type natriuretic peptide .(24,25) 
 
                                    Patients with HFrEF showed elevation in Prothrombin 
time in  45 % of only NYHA class IV patients and 50% in lower (<20%) 
ejection fraction group and only 17% in higher (EF >20%) group. In the HFpEF 
group, only 2 patients showed elevation of  Prothrombin time only with NYHA 
class III&IV and diastolic grading 3. Furman et al (26)showed that the increase 
in the PT-INR >2 signifies risk of death in greater number of cohorts while 
Raurich et al(27) confirmed the same . In our study also there was 100 % 
mortality with patients in league of elevated PT-INR in the HFrEF group. 
                                    Hence the alterations in liver functions are proved beyond 
doubt in this study also linking it to the clinical and echocardiographic 
assessment where the alterations are more pronounced with increasing severity 
and functional class. 
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SUMMARY  
 
1) In HFrEF group, the prevalence of LFT abnormalities was 63% while in the 
in HFpEF group the prevalence was 33%. 
2) HFrEF group presented with hepatocellular pattern of bilirubin elevation with 
more unconjugated bilirubin, transminases while the HFpEF group presented 
with cholestatic pattern of elevation enzymes like GGT and ALP. 
3) Functional NYHA class with greater severity (class III and IV) were 
associated with abnormal LFT values and provided an increasing trend with 
increasing severity in terms of absolute values of  LFT . 
4) Echocardiogram assessment correlated well with the severity of heart failure 
in terms of both HFrEF and HFpEF patients. 
5) Coronary artery disease is the leading cause in HFrEF group while 
hypertensive heart disease led in HFpEF group. 
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CONCLUSION  
 
                            The effect of heart failure on hepatic functions and the cardio 
hepatic interactions that occur in the full spectrum of heart failure needs greater 
elucidation not only for the management of heart failure and its associated 
complications but also to assess the prognosis, need for urgent surgical 
intervention,  the need for ventricular assist devices .This study on prevalence of 
LFT abnormalities and its correlation with functional , echocardiological 
severity may be of help in assessing the heart failure patients even in primary 
health care setting and lead onto better management of the heart failure patients. 
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LIMITATIONS OF THE STUDY 
 
1) The sample size is small. 
2) There  was no division of acute and chronic heart failure. 
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PROFORMA 
 
Name:                                                                                               D.O.A:- 
Age/sex:                                                                                           D.O.D:- 
Hospital no:                                                                                     Phone No: 
Occupation: 
Address: 
History: 
Chest pain   Pedal edema   
Dyspnoea   Dilated neck veins   
Palpitations   Abdominal distension   
Syncope   dyspepsia   
Orthopnoea/PND   Bleeding diathesis   
Jaundice   Bowel disturbances   
          
Past history:  
             H/o liver diseases 
            H/o drug intake(ATT) 
Personal history; 
               smoker-   yes/ no                    alcoholic –yes /no 
 General examination: 
Pallor        Icterus      Cyanosis       Clubbing       Lymphadenopathy      Oedema    
  PULSE   :                             BP :         /         mm Hg         JVP: 
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SYSTEMIC EXAMINATION 
CARDIOVASCULAR SYSTEM 
 
RESPIRATORY SYSTEM 
 
GASTRO INTESTINAL SYSTEM  
 
CNS 
 
INVESTIGATIONS: 
CBC:                                        Urine    Sugar                                              ULTRASOUND 
TC                                                      Albumin 
DC                                                     Deposits 
Hb                                           RFT:   Urea            Creatinine 
Platelets                                   Na-                       K 
ESR 
LIVER FUNCTION 
Tot.bil Direct indirect SGOT SGPT ALP TOT.PROT ALB GLOB PT APTT 
           
           
 
ECG:     
CHEST XRAY:                                  
 
ECHO: 
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MASTER CHART 
HEART FAILURE WITH REDUCED EJECTION FRACTION 
S.N
O 
NAME AG
E 
SE
X 
DIAGNOSIS TOT.BI
L 
UNC.BI
L 
CON.BI
L 
AL
T 
AS
T 
GGT ALP SR.AL
B 
PT(INR
) 
EJ.FRA
C 
CLAS
S 
1 Amalan 62 M MI 3.6 2.2 1.4 786 712 68 58 4 0.9 28 C 
2 Vijayan 68 M MI 2.8 2.2 0.6 680 595 62 42 2.8 0.8 18 D 
3 Mythili 56 F MI 0.9 0.7 0.2 48 39 75 46 3.7 1.1 34 B 
4 Yuvan 40 M MI 1 0.7 0.3 52 45 52 60 3.6 1 36 B 
5 Thamarai 52 F MI 1 0.8 0.2 586 554 65 64 2.2 1 18 D 
6 Seeniappa
n 
68 M MI 4 3.2 0.8 752 702 45 48 2.4 1.5 24 D 
7 Duratchi 60 F MI 0.8 0.6 0.2 52 48 48 54 3.7 0.8 30 B 
8 Senthai 
velan 
65 M MI 0.9 0.8 0.1 50 28 56 50 3.8 0.9 27 C 
9 Ramani 67 F MI 3.2 2.4 0.8 108
6 
992 75 68 3 1.1 18 D 
10 Anthony 59 M MI 1.1 0.8 0.3 48 44 45 72 3.9 1 32 D 
11 Shahila 55 F HEAT STROKE 4.2 3.4 0.8 44 42 454 414 2 1.1 38 B 
12 Meena 65 F VALVULAR 
HEART 
DISESASE 
2.9 1.8 1.1 546 512 79 54 3.1 1.3 20 D 
13 Anban 42 M MYOCARDITI
S 
1 0.8 0.2 486 452 48 50 2.8 1 25 D 
14 Jeyaseelan 38 M MYOCARDITI
S 
0.9 0.7 0.2 42 38 56 52 4.1 0.9 26 C 
15 Mohana 55 F CAD  0.8 0.6 0.2 596 498 64 68 2.4 0.9 23 D 
16 Rasathi 65 F CAD  0.9 0.7 0.2 492 452 512 466 2.5 1.7 18 D 
17 Saraswath
y 
67 F CAD  2.2 1.8 0.4 58 54 65 72 4.2 0.8 27 C 
18 Gopal 70 M CAD  5 3.2 1.8 107
6 
984 452 586 2.2 1.4 18 D 
19 Trace 
meena 
64 F CAD  1.1 0.9 0.2 62 58 56 44 4.2 0.9 32 C 
20 Papathi 74 F CAD  4 3.5 0.5 986 812 57 40 2.1 1 15 C 
21 Nivin 
mark 
59 M CAD 1 0.9 0.1 60 48 46 56 4.2 1 38 B 
22 Thirupathi 75 M CAD 1 0.8 0.2 412 404 72 80 3.8 1.6 24 D 
23 Chandran 65 M CAD 3.9 3 0.9 816 784 56 54 2.4 1 20 D 
24 Pandiamm
al 
66 F CAD 0.9 0.7 0.2 44 48 49 56 3.9 0.9 34 B 
25 Seeniamm
al 
62 F CAD 0.8 0.6 0.2 25 32 66 48 3.9 0.9 36 C 
26 Latha 60 F CAD 0.8 0.6 0.2 46 45 64 52 4 0.8 28 C 
27 Jayanthan 63 M CAD 1 0.8 0.2 48 44 48 56 4.1 0.9 30 C 
28 Gurusamy 76 M CAD 3.8 3 0.8 986 884 44 68 4.2 1.4 26 D 
29 Mannan 45 M VALVULAR 
HEART 
DISESASE 
2.4 2 0.4 54 48 50 52 4.3 1 28 C 
30 Kokila 40 F VALVULAR 
HEART 
DISESASE 
2.6 1.8 0.6 786 612 512 566 2.5 0.9 16 D 
31 Christie 
sheela 
38 F VALVULAR 
HEART 
DISESASE 
2.2 1.8 0.4 52 48 65 52 3.6 0.9 32 C 
32 Anbumathi 44 F VALVULAR 
HEART 
DISESASE 
3.5 2.8 0.7 108
6 
912 408 526 3.7 1.3 24 D 
 
 
 
 
 
106 
 
HEART FAILURE WITH PRESERVED FRACTION 
S.NO NAME AGE SEX DIAGNOS
IS 
TOT.BI
L 
UNCO
N 
CONJ ALT AST ALP GGT SR.AL
B 
PT 
INR 
 DIAS 
DYS 
GR 
CLAS
S 
1 Selvi 66 F HTN/CAD 1.1 0.9 0.2 48 52 82 44 3.5 1 2 B 
2 Meena 75 F HTN/CAD 1 0.8 0.2 45 52 45 48 3.6 1 2 B 
3 Urval 72 F HTN/CAD 2.8 1.5 1.3 52 62 542 486 3 0.9 3 C 
4 Nangai 68 F HTN/CAD 0.9 0.7 0.2 70 68 46 72 4.4 1 2 B 
5 Esakki 59 F HTN/CAD 3.6 1.9 1.7 584 514 414 454 2.7 1.5 3 C 
6 Muneeswar
an 
56 M OBESITY 0.8 0.6 0.2 48 70 55 80 3.7 1.2 2 B 
7 Mariammal 67 F HTN/CAD 1 0.9 0.1 40 34 65 68 3.6 1.1 2 B 
8 Maayan 80 M HTN/CAD 3.2 2 1.2 102 114 482 386 3.6 1 3 C 
9 Nambirajan 65 M HTN/CAD 1 0.9 0.1 64 60 72 81 3.5 0.9 2 B 
10 Yasodhai 71 F HTN/CAD 1 0.8 0.2 58 48 80 56 3.8 1 2 B 
11 Guruvamm
al 
66 F HTN/CAD 1.1 0.9 0.2 62 58 55 48 3.6 1 2 B 
12 Rasiammal 80 F HTN/CAD 0.9 0.6 0.3 64 52 66 66 3.7 0.8 2 B 
13 Balan 76 M HTN/CAD 3.2 2 1.2 414 385 494 478 4 1.1 3 D 
14 Rakku 69 F HTN/CAD 0.9 0.7 0.2 7 80 56 46 3.5 0.9 2 B 
15 Sembaruthi 66 F HTN/CAD 0.8 0.6 0.2 48 40 512 554 2.9 1.6 3 C 
16 Vijaya 68 F HTN/CAD 1 0.8 0.2 36 38 74 34 3.5 0.9 2 B 
17 Lallita 54 F CONS,PE
RI 
3 1.8 1.2 61 65 80 76 3.6 1.1 2 B 
18 Murugan 60 M HTN/CAD 1.1 0.8 0.3 73 58 48 56 4 1 2 B 
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KEY TO MASTER CHART  
 
 
1) S.NO – SERIAL NUMBER 
2)TOT.BIL – TOTAL BILIRUBIN 
3)UNC.BIL – UNCONJUGATED BILIRUBIN 
4)CON.BIL – CONJUGATED BILIRUBIN 
5)AST – ASPARTATE TRANSAMINASE 
6)ALT- ALANINE TRANSAMINASE 
7)GGT - GAMMA GLUTAMYL TRANSFERASE 
8)ALP- AKALINE PHOSHATASE 
9) EJ.FR- EJECTION FRACTION 
10) CLASS- NYHA HEART FAILURE CLASSIFICATION 
11)DIA.DYS- DIASTOLIC DYSFUNCTION GRADING  
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ABBREVIATIONS 
1) HF – Heart Failure  
2) HFrEF – Heart Failure with reduced ejection fraction 
3)HFpEF – Heart Failure with preserved ejection fraction 
4) AST – Aspartate Transaminase 
5) ALT – Alanine  Transaminase 
6)GGT – Gamma Glutamyl Transferase 
7)ALP –Alkaline Phosphatase 
8) PT-INR – Prothrombin Time International Normalized Ratio 
9)RAAS –Renin Angiotensin Aldosterone System 
10) AT –Angiotensin 
11)ACEI –Angiotensin Converting Enzyme Inhibitor 
12)ET – Endothelin 
13)AVP –Arginine Vasopressin  
14)NYHA – New York Heart Association 
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CONSENT FORM 
 
 
